copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Home - Curis, Inc Curis is focused on the development and commercialization of innovative therapeutics for the treatment of cancer
Company Overview - Curis, Inc At Curis, we apply this meaning to cancer, by developing novel therapies for slowing or preventing the progression of cancer and prolonging life – or closing and curi͒ng cancer
Pipeline Overview - Curis, Inc Indicates a program included in the Curis intellectual property portfolio, but not currently designated as a priority for clinical development
Emavusertib (CA-4948) - Curis, Inc As part of the collaboration with Aurigene, in October 2015, Curis exclusively licensed a program of orally-available, small molecule inhibitors of IRAK4 kinase, including emavusertib (CA-4948) For more information on current trials click here
About - Curis, Inc We are a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer Our clinical stage drug candidates are:
Curis Provides Third Quarter 2024 Business Update Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor Emavusertib is currently undergoing testing in the Phase 1 2 TakeAim Lymphoma
Management - Curis, Inc Mark Noel » Vice President, Technology Management Intellectual Property Nancy Soohoo » Vice President General Counsel Frank W Waligora » Vice President, Technical Operations
Contact - Curis, Inc Curis Inc 128 Spring Street Building C- Suite 500 Lexington, MA 02421 (617) 503-6500 info@curis com